Inroxim CV Tablet is a combination antibiotic formulation containing Cefuroxime 500 mg and Clavulanic Acid 125 mg, designed to treat a broad spectrum of bacterial infections. Cefuroxime, a second-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, thereby effectively targeting both Gram-positive and Gram-negative pathogens. Clavulanic Acid, a potent beta-lactamase inhibitor, enhances the efficacy of Cefuroxime by preventing enzymatic degradation of the antibiotic, especially against beta-lactamase-producing resistant strains. This synergistic combination is indicated for the management of respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, sinusitis, and certain sexually transmitted infections. Inroxim CV Tablet is administered orally and is generally well-tolerated, with common adverse effects including gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. It is contraindicated in patients with known hypersensitivity to cephalosporins, penicillins, or beta-lactamase inhibitors. Caution is advised in individuals with a history of allergic reactions or renal impairment. Appropriate dosing and duration of therapy should be determined by a healthcare professional based on the severity and type of infection. Inroxim CV Tablet provides an effective therapeutic option for combating resistant bacterial infections when used in accordance with clinical guidelines.